CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Cash Flow Y/Y Annual
Cytokinetics Incorporated  (CYTK)
Other Ticker:  
 
 

CYTK's Net Cash Flow Growth by Quarter and Year

Cytokinetics Incorporated's Net Cash Flow results by quarter and year




CYTK Net Cash Flow (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
IV Quarter December - -39.06 22.10 -117.83
III Quarter September 31.05 12.61 53.41 139.68
II Quarter June -34.20 -21.79 -7.44 11.36
I Quarter March 36.03 2.76 -38.39 13.34
FY   32.88 -45.48 29.68 46.55



CYTK Net Cash Flow third quarter 2023 Y/Y Growth Comment
Cytokinetics Incorporated reported Net Cash Flow surge of 146.26% year on year in the third quarter 2023, to $ 31.05 millions, this is lower than Cytokinetics Incorporated's recent average Net Cash Flow surge of 5564.56%.

Looking into third quarter 2023 results within Major Pharmaceutical Preparations industry 13 other companies have achieved higher Net Cash Flow growth. While Cytokinetics Incorporated' s Net Cash Flow doubling of 146.26% ranks overall at the positon no. 272 in the third quarter 2023.


CYTK Net Cash Flow ( Y/Y Growth %) 2023
 2022 2021 2020
IV Quarter December - - - -
III Quarter September 146.26 % -76.39 % -61.76 % -
II Quarter June - - - -
I Quarter March 1205.43 % - - -
FY   - - -36.24 % -

Financial Statements
Cytokinetics Incorporated's third quarter 2023 Net Cash Flow $ 31.05 millions CYTK's Income Statement
Cytokinetics Incorporated's third quarter 2022 Net Cash Flow $ 12.61 millions Quarterly CYTK's Income Statement
New: More CYTK's historic Net Cash Flow Growth >>


CYTK Net Cash Flow (Quarter on Quarter Growth %)

 2023
 2022 2021 2020
IV Quarter December - - -58.62 % -
III Quarter September - - - 1129.58 %
II Quarter June - - - -14.84 %
I Quarter March - -87.51 % - -
FY (Year on Year)   - - -36.24 % -


Go to CYTK Cash flow Statement >> Back to CYTK Growth rate Comparisons >>


Net Cash Flow third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #14
Healthcare Sector #38
Overall #272

Net Cash Flow Y/Y Growth Statistics
High Average Low
78603.51 % 5564.56 % -253.24 %
(Dec. 30, 2015)   (Dec 31 2022)
Net Cash Flow third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #14
Healthcare Sector #38
Overall #272
Net Cash Flow Y/Y Growth Statistics
High Average Low
78603.51 % 5564.56 % -253.24 %
(Dec. 30, 2015)   (Dec 31 2022)

Net Cash Flow by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Cytokinetics Incorporated's Q/Q Net Cash Flow Growth


Net Cash Flow Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


CYTK's III. Quarter Q/Q Net Cash Flow Comment
III. Quarter 2023Cyclical Cytokinetics Incorporated in the circumstances net cash outflow of $ 31.05 millionsCyclical circumstances seem to have led to Cytokinetics Incorporated's rebound to recovery, as CYTK clinchesNet Cash Flow of $ 31.05 millions in the III. Quarter 2023 coming of net cash outflow-34.20 millions in the second quarter. Cytokinetics Incorporated announced in the III. Quarter 2023 Net Cash Flow of $ 31.05 millions compare to net cash outflow recorded in previos quarter.

Within Major Pharmaceutical Preparations industry Cytokinetics Incorporated achieved highest sequential Net Cash Flow growth. While Cytokinetics Incorporated's Net Cash Flow growth quarter on quarter, overall rank is .


Net Cash Flow Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Net Cash Flow Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Net Cash Flow Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


CYTK's III. Quarter Q/Q Net Cash Flow Comment
III. Quarter 2023Seasonal Cytokinetics Incorporated in the circumstances net cash outflow of $ 31.05 millionsSeasonal circumstances seem to have led to Cytokinetics Incorporated's restoration of positive trends, as CYTK deliverNet Cash Flow of $ 31.05 millions in the III. Quarter 2023 emanate net cash outflow-34.20 millions in the second quarter. Cytokinetics Incorporated announced in the III. Quarter 2023 Net Cash Flow of $ 31.05 millions compare to net cash outflow recorded in previos quarter.

Within Major Pharmaceutical Preparations industry Cytokinetics Incorporated achieved highest sequential Net Cash Flow growth. While Cytokinetics Incorporated's Net Cash Flow growth quarter on quarter, overall rank is .


Cytokinetics Incorporated's 12 Months Net Cash Flow Growth Year on Year


Net Cash Flow TTM Growth

12 Months Ending
(Sep 30 2023)		 12 Months Ending
(Jun 30 2023)		 12 Months Ending
(Mar 31 2023)		 12 Months Ending
(Dec 31 2022)		 12 Months Ending
(Sep 30 2022)
Cumulative Net Cash Flow 12 Months Ending $ -6.17 $ -24.62 $ -12.21 $ -45.48 $ 15.68
Y / Y Net Cash Flow Growth (TTM) - - - - -
Year on Year Net Cash Flow Growth Overall Ranking # # # # #
Seqeuential Net Cash Flow Change (TTM) - - - - -72.24 %
Seq. Net Cash Flow Growth (TTM) Overall Ranking # 505 # 325 # 190 # 116 # 239

New: More CYTK's historic Net Cash Flow Growth >>



Cumulative Net Cash Flow growth Comment
Cytokinetics Incorporated realized trailing twelve months net cash outflow of $ -6 millions, in the Sep 30 2023, compare to Net Cash Flow of $ 16 millions a year ago.

Cytokinetics Incorporated achieved highest trailing twelve month year on year Net Cash Flow growth. While overall Net Cash Flow growth ranking, remained unchanged compare to the previous quarter at no. .

Net Cash Flow TTM Q/Q Growth Statistics
High Average Low
78603.51 %
5564.56 %
-253.24 %
 

Net Cash Flow TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Net Cash Flow TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Net Cash Flow TTM Q/Q Growth Company Ranking
Within: No.
Industry # 30
Sector # 82
S&P 500 # 505
Cumulative Net Cash Flow growth Comment
Cytokinetics Incorporated realized trailing twelve months net cash outflow of $ -6 millions, in the Sep 30 2023, compare to Net Cash Flow of $ 16 millions a year ago.

Cytokinetics Incorporated achieved highest trailing twelve month year on year Net Cash Flow growth. While overall Net Cash Flow growth ranking, remained unchanged compare to the previous quarter at no. .

Net Cash Flow TTM Q/Q Growth Statistics
High Average Low
78603.51 %
5564.56 %
-253.24 %
 


Net Cash Flow TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Net Cash Flow TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Net Cash Flow TTM Q/Q Growth Company Ranking
Within: No.
Industry # 30
Sector # 82
S&P 500 # 505




Other Net Cash Flow Growth
Major Pharmaceutical Preparations Industry Net Cash Flow Growth Trends and Statistics
Healthcare Sector Net Cash Flow Growth Statistics
Net Cash Flow Growth Trends for overall market
CYTK's Net Cash Flow Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Net Cash Flow Growth
Lowest Ranking Net Cash Flow Growth
Net Cash Flow Growth for CYTK's Competitors
Net Cash Flow Growth for Cytokinetics Incorporated's Suppliers
Net Cash Flow Growth for CYTK's Customers

You may also want to know
CYTK's Annual Growth Rates CYTK's Profitability Ratios CYTK's Asset Turnover Ratio CYTK's Dividend Growth
CYTK's Roe CYTK's Valuation Ratios CYTK's Financial Strength Ratios CYTK's Dividend Payout Ratio
CYTK's Roa CYTK's Inventory Turnover Ratio CYTK's Growth Rates CYTK's Dividend Comparisons



Companies with similar Net Cash Flow doubling for the quarter ending Sep 30 2023 within Healthcare SectorY/Y Change %Net Cash Flow for the quarter ending Sep 30 2023
Orasure Technologies Inc249.29%$ 249.293 millions
Teladoc Health Inc 228.82%$ 228.824 millions
Immunitybio inc 218.18%$ 218.182 millions
Axogen inc 205.37%$ 205.366 millions
Amarin Corp Plcuk202.58%$ 202.576 millions
Trevena inc 175.52%$ 175.523 millions
Ikena Oncology Inc 173.39%$ 173.390 millions
Neurocrine Biosciences Inc 173.01%$ 173.006 millions
Aquestive Therapeutics Inc 160.06%$ 160.063 millions
Actavia Life Sciences Inc 151.37%$ 151.374 millions
Cytokinetics Incorporated146.32%$ 146.316 millions
Avanos Medical Inc 140.95%$ 140.952 millions
Lantheus Holdings Inc 134.62%$ 134.620 millions
Skye Bioscience Inc 125.55%$ 125.554 millions
Viridian Therapeutics Inc 122.74%$ 122.742 millions
Durect Corp121.69%$ 121.694 millions
Regeneron Pharmaceuticals Inc 118.81%$ 118.815 millions
Ensign Group Inc105.70%$ 105.703 millions
Vertex Pharmaceuticals Inc103.68%$ 103.679 millions
Tenaya Therapeutics Inc 96.61%$ 96.613 millions
Ainos Inc 94.42%$ 94.423 millions
Merck and Co Inc 93.77%$ 93.775 millions
Henry Schein Inc 93.33%$ 93.333 millions
Insulet Corporation90.23%$ 90.226 millions
Benitec Biopharma Inc 87.53%$ 87.531 millions
Anika Therapeutics Inc 86.37%$ 86.373 millions
Cadre Holdings inc 82.02%$ 82.025 millions
Vistagen Therapeutics Inc 73.30%$ 73.300 millions


Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com